Northeast Pharmaceutical Group Co., Ltd. specializes in the production and marketing of pharmaceutical ingredients and preparations. The group's products include antibiotics, vitamins, cardiovascular treatments, anesthetics, medical plants, etc. China accounts for 86.3% of net sales.

Employees

5,727

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
30/26/30	CN¥4.340	+0.23%	99,23,168
29/26/29	CN¥4.330	-1.59%	85,93,911
28/26/28	CN¥4.400	0.00%	77,08,744
27/26/27	CN¥4.400	-2.44%	74,99,900
26/26/26	CN¥4.510	+0.45%	70,90,523

End-of-day quote Shenzhen S.E.

More quotes

End-of-day quote Shenzhen S.E. 30/10/2026			5-day change	1st Jan Change
4.340 ^CNY	+0.23%		-3.34%	-16.86%

28/10	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2026	CI
24/08	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI

Market Cap	619.29Cr 93Cr 83Cr 77Cr 69Cr 129.82Cr 8.83TCr 132.25Cr 914.08Cr 366.94Cr 4.65TCr 349.19Cr 341.76Cr 15TCr	P/E 2024	18.2x	P/E 2025	29x
Enterprise Value	470.23Cr 71Cr 63Cr 58Cr 53Cr 99Cr 6.71TCr 100.42Cr 694.07Cr 278.62Cr 3.53TCr 265.14Cr 259.51Cr 11TCr	EV / Sales 2024	0.62x	EV / Sales 2025	0.84x
Free-Float	39.09%	Yield 2024	1.9%	Yield 2025	1.05%

28/10	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2026	CI
24/08	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
16/06	Northeast Pharmaceutical Group Co., Ltd. Announces Final Cash Dividend on A Shares for 2025, Payable on 23 June 2026	CI
27/04	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03/04	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02/04	Northeast Pharmaceutical Group Co., Ltd. announces Annual dividend, payable on June 23, 2026	CI
28/25/28	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
09/25/09	Northeast Pharmaceutical Unit Gets Clinical Trial Approval for Glioma Treatment	MT
08/25/08	Northeast Pharmaceutical Appoints CFO	MT
02/25/02	Northeast Pharmaceutical CFO Resigns	MT
26/25/26	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
05/25/05	Northeast Pharmaceutical Gets Nod to Market Antiobiotic in Europe	MT
28/25/28	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI

1 day	+0.23%
1 week	-3.34%
Current month	-8.82%
1 month	-7.46%
3 months	-5.86%
6 months	-12.50%
Current year	-16.86%

Northeast Pharmaceutical Group Co., Ltd. Share Price

Stocks

000597

CNE0000009G0

Pharmaceuticals

Valuation: Northeast Pharmaceutical Group Co., Ltd.

Chart: Northeast Pharmaceutical Group Co., Ltd.

Latest news: Northeast Pharmaceutical Group Co., Ltd.

Press Releases: Northeast Pharmaceutical Group Co., Ltd.

Quotes and Performance

Price Extremes

Managers and Directors: Northeast Pharmaceutical Group Co., Ltd.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 week	4.27	4.54
1 month	4.27	5.07
Current year	4.09	5.73
1 year	4.09	5.93
3 years	3.72	6.69
5 years	3.72	9.3
10 years	3.72	9.3

Manager	Title	Age	Since
Yong Gang Cai CEO	Chief Executive Officer	46	21/01/2025
Xin Li DFI	Director of Finance/CFO	46	06/09/2025
Dong Sheng Yan IRC	Investor Relations Contact	42	01/07/2024

Director	Title	Age	Since
Kai Zhou CHM	Chairman	62	21/01/2025
Xin Hua Ao BRD	Director/Board Member	62	18/07/2018
Cheng Ren Huang BRD	Director/Board Member	62	18/07/2018

Date	Insider	Type	Main position	Quantity	% Market Cap.
01/06/22	Zhengwei	Buy		36,000	0.0027%
26/05/22	Yan Liu	Buy	Executive/Senior Manager	100	0.0000%
25/05/22	Zhengwei	Buy		28,100	0.0021%

	2024	2025
Net sales	750.26Cr 112.72Cr 100.95Cr 93Cr 84Cr 157.28Cr 11TCr 160.22Cr 1.11TCr 444.54Cr 5.63TCr 423.03Cr 414.04Cr 18TCr	707.49Cr 106.3Cr 95Cr 88Cr 79Cr 148.31Cr 10TCr 151.09Cr 1.04TCr 419.2Cr 5.31TCr 398.92Cr 390.44Cr 17TCr
Net income	41Cr 6.16Cr 5.51Cr 5.07Cr 4.6Cr 8.59Cr 584.68Cr 8.75Cr 60Cr 24Cr 307.56Cr 23Cr 23Cr 969.93Cr	26Cr 3.91Cr 3.5Cr 3.22Cr 2.92Cr 5.45Cr 371.01Cr 5.55Cr 38Cr 15Cr 195.16Cr 15Cr 14Cr 615.47Cr
Net Debt	-287.58Cr -43Cr -39Cr -36Cr -32Cr -60Cr -4.1TCr -61Cr -424.47Cr -170.4Cr -2.16TCr -162.15Cr -158.7Cr -6.81TCr	-149.05Cr -22Cr -20Cr -18Cr -17Cr -31Cr -2.13TCr -32Cr -220Cr -88Cr -1.12TCr -84Cr -82Cr -3.53TCr

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NORTHEAST PHARMACEUTICAL GROUP CO., LTD.	+0.23%	-3.34%	-21.52%	-18.27%	93Cr
ELI LILLY AND COMPANY	+2.84%	+11.24%	+67.74%	+150.40%	1,22400Cr
JOHNSON & JOHNSON	-0.63%	+3.73%	+44.75%	+86.12%	66TCr
ABBVIE INC.	+0.91%	+2.90%	+28.80%	+107.14%	51TCr
ROCHE HOLDING AG	+0.42%	+3.20%	+54.15%	+67.18%	39TCr
MERCK & CO., INC.	+1.82%	+3.25%	+73.84%	+46.07%	36TCr
NOVARTIS AG	+1.12%	+4.52%	+35.30%	+58.08%	30TCr
ASTRAZENECA PLC	+6.96%	+8.86%	+11.27%	+36.62%	27TCr
AMGEN INC.	+0.81%	+6.37%	+60.01%	+77.53%	25TCr
GILEAD SCIENCES, INC.	+3.10%	+10.08%	+45.03%	+120.87%	21TCr
Average	+1.87%	+1.96%	+39.94%	+73.17%	41.78TCr
Weighted average by Cap.	+1.83%	+3.04%	+50.96%	+98.25%